A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis

Herman, D.; Garay, Ricardo P.; Gal, Martine Le

doi:10.1016/s0165-5876(96)01457-7

Cited by 33 publications

(22 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the severity of rhinitis was not exactly based on the ARIA criteria, we proposed a simpler methodology for a study in such a large number of patients. VAS have been extensively used to assess the severity of rhinitis [10, 15,21,22,23] as well as the efficacy of therapeutic interventions [10, 14, 24, 25]. The use of VAS has also been recently proposed by the Joint Task Force on Practice Parameters for the symptom severity assessment of allergic rhinitis [26].…”

Section: Discussionmentioning

confidence: 99%

Implementation of Guidelines for Allergic Rhinitis in Specialist Practices

Bousquet

Bodez

Gehano

et al. 2009

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Guidelines for allergic rhinitis are more effective than free-treatment choice in the control of seasonal allergic rhinitis. Objective: To validate the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines in the treatment of intermittent and persistent allergic rhinitis induced by pollens. Design: A multicenter, open-label, parallel, pragmatic randomized study compared two therapeutic strategies during a 2-week treatment course. In the first strategy (‘guidelines group’), 417 patients were treated according to ARIA with ebastine as oral antihistamine. In the second strategy (‘free-choice treatment group’), investigators had a free choice for the treatment of 422 patients. Main Outcome Measures: Quality of life measured using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), work productivity and daily symptom medication scores. Results: 94.2% patients returned the baseline visit questionnaires and 88.6% returned the posttreatment period questionnaires. RQLQ scores were similar in the two groups at baseline. After treatment, there were improvements in the overall score and in all domains in both treatment groups. According to pragmatic methodology, the improvements show that the guidelines group (–1.70 ± 1.20) is more effective than the free-choice treatment group (–1.52 ± 1.22) with a γ risk of 2%. Individual RQLQ scores, work productivity, and daily symptom scores were significantly improved in the guidelines group by comparison to the free-choice treatment group. Conclusion: A treatment based on ARIA guidelines offers patients a significant improvement in comparison to the use of a nonstandardized treatment regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Implementation of Guidelines for Allergic Rhinitis in Specialist Practices

Bousquet

Bodez

Gehano

et al. 2009

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Visual analogue scales are quantitative measures largely validated in many diseases (1401,1402). The scales have been extensively used to assess the severity of rhinitis (728,(1403)(1404)(1405)(1406) as well as the efficacy of therapeutic interventions (118,(1406)(1407)(1408)(1409)(1410). The VAS was proposed by the Joint Task Force on Practice Parameters for the symptom severity assessment of allergic rhinitis (118).…”

Section: Assessment Of the Severity And Control Of Rhinitismentioning

confidence: 99%

“…However, although there is a beneficial effect upon symptoms in the organ to which they are administered, they usually have little effect elsewhere. These drugs are useful in children with symptoms limited to the nose or the eyes (1408,2233,2234).…”

Section: Treatmentmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,867

1,761

View full text Add to dashboard Cite

“…42 Azelastine is indicated for pediatric patients ages 5-12 years. Unfortunately, some patients complain of a bitter taste.…”

Section: Second Generation Antihistaminesmentioning

confidence: 99%

Management of Allergic Rhinitis

Sausen

Marks

Sausen

et al. 2005

The Journal of Pediatric Pharmacology and Therapeutics

View full text Add to dashboard Cite

ABBREVIATIONS: EIB, exercise-induced bronchospasm; IL4, interleukin 4; IL5, interleukin 5; MFNS, mometasone furoate nasal spray; RANTES, regulated upon activation normal T-cell expressed and secreted; QOL, quality of life Allergic rhinitis is the most common chronic childhood disease. Reduced quality of life is frequently caused by this IgE-mediated disease, including sleep disturbance with subsequent decreased school performance. Asthma and exercise-induced bronchospasm are commonly seen concurrently with allergic rhinitis, and poorly controlled allergic rhinitis negatively affects asthma outcomes. Nonsedating antihistamines or intranasal azelastine are effective agents to manage allergic rhinitis, often in combination with oral decongestants. For moderate to severe persistent disease, intranasal corticosteroids are the most effective agents. Some patients require concomitant intranasal corticosteroids and nonsedating antihistamines for optimal management. Other available agents include leukotriene receptor antagonists, intranasal cromolyn, intranasal ipratropium, specific immunotherapy, and anti-IgE therapy.

show abstract

A randomized double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis

Cited by 33 publications

References 4 publications

Implementation of Guidelines for Allergic Rhinitis in Specialist Practices

Implementation of Guidelines for Allergic Rhinitis in Specialist Practices

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Management of Allergic Rhinitis

Contact Info

Product

Resources

About